Literature DB >> 19098892

Acute hepatitis in a patient with cirrhosis and hepatocellular carcinoma treated with sorafenib.

Lucia Llanos, Pablo Bellot, Pedro Zapater, Miguel Pérez-Mateo, Jose Such.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19098892     DOI： 10.1038/ajg.2008.41

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN： 0002-9270            Impact factor:   10.864


× No keyword cloud information.
  7 in total

Review 1.  Hepatotoxicity of tyrosine kinase inhibitors: clinical and regulatory perspectives.

Authors:  Rashmi R Shah; Joel Morganroth; Devron R Shah
Journal:  Drug Saf       Date:  2013-07       Impact factor: 5.606

2.  Fatal case of sorafenib-associated idiosyncratic hepatotoxicity in the adjuvant treatment of a patient with renal cell carcinoma.

Authors:  B P Fairfax; S Pratap; I S D Roberts; J Collier; R Kaplan; A M Meade; A W Ritchie; T Eisen; V M Macaulay; A Protheroe
Journal:  BMC Cancer       Date:  2012-12-11       Impact factor: 4.430

3.  Targeting the PDGF signaling pathway in the treatment of non-malignant diseases.

Authors:  Carl-Henrik Heldin
Journal:  J Neuroimmune Pharmacol       Date:  2013-06-25       Impact factor: 7.285

4.  Sorafenib-induced liver failure: a case report and review of the literature.

Authors:  Anneleen Van Hootegem; Chris Verslype; Werner Van Steenbergen
Journal:  Case Reports Hepatol       Date:  2011-12-12

Review 5.  Tyrosine kinase inhibitors: friends or foe in treatment of hepatic fibrosis?

Authors:  Kai Qu; Tian Liu; Ting Lin; Xing Zhang; Ruixia Cui; Sinan Liu; Fandi Meng; Jingyao Zhang; Minghui Tai; Yong Wan; Chang Liu
Journal:  Oncotarget       Date:  2016-10-11

6.  Herb-Drug Interaction between the Traditional Hepatoprotective Formulation and Sorafenib on Hepatotoxicity, Histopathology and Pharmacokinetics in Rats.

Authors:  Chin-Tsung Ting; Yung-Yi Cheng; Tung-Hu Tsai
Journal:  Molecules       Date:  2017-06-22       Impact factor: 4.411

Review 7.  New Insight into the Anti-liver Fibrosis Effect of Multitargeted Tyrosine Kinase Inhibitors: From Molecular Target to Clinical Trials.

Authors:  Kai Qu; Zichao Huang; Ting Lin; Sinan Liu; Hulin Chang; Zhaoyong Yan; Hongxin Zhang; Chang Liu
Journal:  Front Pharmacol       Date:  2016-01-18       Impact factor: 5.810
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.